Compare PXED & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | BBNX |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.1M | 997.9M |
| IPO Year | 2025 | 2025 |
| Metric | PXED | BBNX |
|---|---|---|
| Price | $23.83 | $17.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $40.75 | $24.24 |
| AVG Volume (30 Days) | 78.4K | ★ 927.8K |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | $1.56 | $25.74 |
| Revenue Next Year | $3.25 | $44.51 |
| P/E Ratio | $14.07 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $23.42 | $8.80 |
| 52 Week High | $38.19 | $32.71 |
| Indicator | PXED | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 43.86 |
| Support Level | N/A | $15.76 |
| Resistance Level | $30.79 | $18.20 |
| Average True Range (ATR) | 0.86 | 0.87 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 10.16 | 37.35 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.